A European citizens’ initiative aimed at promoting psychedelic-assisted treatments for mental health disorders has been registered by the European Commission. The initiative, dubbed “PsychedeliCare,” was registered on Sept. 11, according to the European Commission’s official website, in a bid to establish a transnational legal framework around psychedelic therapy in the …
Psyence Biomedical Ltd (Nasdaq: PBM) is poised to hit several psilocybin-related “milestones” in coming months, including the acquisition of drug developer Clairvoyant, the launch of research into psilocybin as a treatment for substance use disorders and ongoing clinical trials in Australia for psilocybin in treating adjustment disorder. CEO Dr. Neil …
The team that was banned by the SEC for the troubled C3 International deal, is already back with a new variation called C3 Pharmaceuticals. It’s the same executives and the same drug, but with a slightly different name planning to list on the Canadian Securities Exchange. The new iteration of C3 Pharmaceuticals, …
Calgary-based High Tide Inc. (Nasdaq: HITI) (TXSV: HITI) continues to grow its store count alongside its balance sheet, all while some of its largest competitors file for bankruptcy or shutter locations amid industry headwinds. On an earnings call Monday, High Tide CEO Raj Grover said the company has opened 21 …